Lucid Diagnostics Inc. (LUCD): Price and Financial Metrics

Lucid Diagnostics Inc. (LUCD): $0.81

0.05 (-5.86%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

F

LUCD Price/Volume Stats

Current price $0.81 52-week high $1.85
Prev. close $0.86 52-week low $0.78
Day low $0.78 Volume 358,200
Day high $0.88 Avg. volume 140,944
50-day MA $1.16 Dividend yield N/A
200-day MA $1.33 Market Cap 39.03M

LUCD Stock Price Chart Interactive Chart >


Lucid Diagnostics Inc. (LUCD) Company Bio


Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company's lead products include EsoGuard, a laboratory developed esophageal DNA test that examines individuals DNA molecules for the presence or absence of cytosine methylation; and EsoCheck, a cell collection device that collects cells of targeted region of the esophagus. Lucid Diagnostics Inc. was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.


LUCD Latest News Stream


Event/Time News Detail
Loading, please wait...

LUCD Latest Social Stream


Loading social stream, please wait...

View Full LUCD Social Stream

Latest LUCD News From Around the Web

Below are the latest news stories about LUCID DIAGNOSTICS INC that investors may wish to consider to help them evaluate LUCD as an investment opportunity.

The 3 Most Undervalued Penny Stocks to Buy in December

We cannot end the year without adding a few penny stocks to our portfolio to take advantage of the opportunities coming up in the next cycle. Of course, we must rely on our investment thesis and our own analysis, but here I am to tell you a little about these undervalued penny stocks that are worth analyzing and evaluating to add to our portfolio. Let’s take a brief look. PAVmed (PAVM) Source: venusvi / Shutterstock.com PAVmed (NASDAQ:PAVM) is making waves as one of the undervalued penny stocks

Yahoo | December 17, 2023

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced that three manuscripts providing interim results from the Prospective REView of Esophageal Precancer DetectioN in AT-Risk Patients (PREVENT) Registry, the CLinical Utility of EsoGuard (CLUE) study, and full data from the San Antonio Firefighter study, have been published—

Yahoo | December 12, 2023

PAVmed Provides Additional Details for Upcoming Stock Dividend to Shareholders

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors today provided additional details on the previously announced dividend of common stock of its majority-owned subsidiary, Lucid Diagnostics Inc. (Nasdaq: LUCD) for PAVmed shareholders.

Yahoo | December 11, 2023

PAVmed Announces Dividend of Lucid Diagnostics Common Stock and Reverse Stock Split

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors today announced a dividend of approximately 3.3 million shares of common stock of its majority-owned subsidiary, Lucid Diagnostics Inc. (Nasdaq: LUCD), which equals the number of shares PAVmed will receive in the contemporaneous partial settlement of outstanding intercompany debt owed to PAVmed by Lucid.

Yahoo | December 4, 2023

PAVmed Inc. (NASDAQ:PAVM) Q3 2023 Earnings Call Transcript

PAVmed Inc. (NASDAQ:PAVM) Q3 2023 Earnings Call Transcript November 15, 2023 Operator: Good day, and welcome to the PAVmed Third Quarter 2023 Business Update Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today’s remarks, there will be an opportunity to ask questions. [Operator Instructions] Please also note that today’s event […]

Yahoo | November 20, 2023

Read More 'LUCD' Stories Here

LUCD Price Returns

1-mo -27.03%
3-mo N/A
6-mo -33.61%
1-year -40.44%
3-year N/A
5-year N/A
YTD -42.55%
2023 3.68%
2022 -74.67%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!